Osaic Holdings
MLTX icon

Osaic Holdings’s MoonLake Immunotherapeutics MLTX Stock Holding History

Osaic Holdings’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.44K Sell
485
-15,420
-97% -$280K ﹤0.01% 6639
2026
Q1 		$296K Buy
15,905
+6,920
+77% +$115K ﹤0.01% 3817
2025
Q4 		$118K Buy
8,985
+8,898
+10,228% +$105K ﹤0.01% 4569
2025
Q3 		$3.05K Buy
87
+37
+74% +$1.93K ﹤0.01% 6996
2025
Q2 		$2.36K Sell
50
-25
-33% -$1.02K ﹤0.01% 6871
2025
Q1 		$2.93K Hold
75
– – ﹤0.01% 6443
2024
Q4 		$4.06K Hold
75
– – ﹤0.01% 6302
2024
Q3 		$3.78K Hold
75
– – ﹤0.01% 6336
2024
Q2 		$3.3K Sell
75
-25
-25% -$1.06K ﹤0.01% 6378
2024
Q1 		$5.02K Sell
100
-1,917
-95% -$104K ﹤0.01% 6090
2023
Q4 		$122K Buy
2,017
+708
+54% +$36.5K ﹤0.01% 4288
2023
Q3 		$74.6K Buy
1,309
+506
+63% +$27.9K ﹤0.01% 4727
2023
Q2 		$41K Buy
803
+727
+957% +$19.6K ﹤0.01% 5067
2023
Q1 		$1.62K Buy
+76
New +$1.28K ﹤0.01% 6797

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Osaic Holdings's MLTX Position: Q2 2026 in Review

Osaic Holdings reduced its MoonLake Immunotherapeutics (MLTX) stake by 97% in Q2 2026, selling an estimated $280K and leaving 485 shares worth $9.44K. The position accounts for ﹤0.01% of the portfolio, ranked #6639.

Osaic Holdings first reported a position in MLTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $296K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Osaic Holdings held 485 shares of MoonLake Immunotherapeutics worth $9.44K as of Q2 2026.
  • Osaic Holdings sold 15,420 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $280K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #6639 holding.
  • Osaic Holdings first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 14 quarters since.
  • Osaic Holdings's MoonLake Immunotherapeutics position peaked at $296K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.